T
79.66
2.68 (3.48%)
| Previous Close | 76.98 |
| Open | 76.92 |
| Volume | 419,691 |
| Avg. Volume (3M) | 600,279 |
| Market Cap | 3,381,495,808 |
| Price / Earnings (Forward) | 106.38 |
| Price / Sales | 5.98 |
| Price / Book | 8.01 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -44.91% |
| Operating Margin (TTM) | -33.55% |
| Diluted EPS (TTM) | -2.70 |
| Quarterly Revenue Growth (YOY) | 183.70% |
| Total Debt/Equity (MRQ) | 21.13% |
| Current Ratio (MRQ) | 5.57 |
| Operating Cash Flow (TTM) | -65.89 M |
| Levered Free Cash Flow (TTM) | -36.41 M |
| Return on Assets (TTM) | -16.05% |
| Return on Equity (TTM) | -33.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Tarsus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.1
| Analyst Consensus | 3.0 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.10 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 3.25% |
| % Held by Institutions | 110.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 105.00 (Oppenheimer, 31.81%) | Buy |
| Median | 97.50 (22.40%) | |
| Low | 90.00 (Guggenheim, 12.98%) | Buy |
| Average | 97.50 (22.40%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 72.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 25 Feb 2026 | 90.00 (12.98%) | Buy | 72.65 |
| Oppenheimer | 25 Feb 2026 | 105.00 (31.81%) | Buy | 72.65 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZAMIAN BOBAK R. | - | 68.26 | -34,603 | -2,360,489 |
| FARROW JEFFREY S | - | 68.26 | -6,430 | -438,798 |
| LIN ELIZABETH YEU | - | 68.26 | -1,144 | -78,067 |
| LINK WILLIAM J PHD | - | 68.90 | -12,500 | -861,250 |
| MOTTIWALA AZIZ | - | 68.26 | -13,056 | -890,969 |
| NEERVANNAN SESHADRI | - | 67.32 | -14,313 | -963,576 |
| WAHL BRYAN | - | 68.26 | -12,440 | -848,932 |
| WHITFIELD DIANNE C. | - | 68.26 | -12,274 | -837,603 |
| Aggregate Net Quantity | -106,760 | |||
| Aggregate Net Value ($) | -7,279,684 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 68.12 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| NEERVANNAN SESHADRI | Officer | 20 Mar 2026 | Automatic sell (-) | 2,989 | 64.51 | 192,820 |
| AZAMIAN BOBAK R. | Officer | 19 Mar 2026 | Sell (-) | 11,964 | 66.75 | 798,597 |
| FARROW JEFFREY S | Officer | 19 Mar 2026 | Sell (-) | 2,186 | 66.75 | 145,916 |
| LIN ELIZABETH YEU | Officer | 19 Mar 2026 | Sell (-) | 390 | 66.75 | 26,033 |
| MOTTIWALA AZIZ | Officer | 19 Mar 2026 | Sell (-) | 4,440 | 66.75 | 296,370 |
| NEERVANNAN SESHADRI | Officer | 19 Mar 2026 | Sell (-) | 4,589 | 66.75 | 306,316 |
| WAHL BRYAN | Officer | 19 Mar 2026 | Sell (-) | 4,231 | 66.75 | 282,419 |
| WHITFIELD DIANNE C. | Officer | 19 Mar 2026 | Sell (-) | 4,174 | 66.75 | 278,615 |
| AZAMIAN BOBAK R. | Officer | 18 Mar 2026 | Sell (-) | 11,667 | 68.24 | 796,156 |
| FARROW JEFFREY S | Officer | 18 Mar 2026 | Sell (-) | 2,133 | 68.24 | 145,556 |
| LIN ELIZABETH YEU | Officer | 18 Mar 2026 | Sell (-) | 379 | 68.24 | 25,863 |
| MOTTIWALA AZIZ | Officer | 18 Mar 2026 | Sell (-) | 4,330 | 68.24 | 295,479 |
| NEERVANNAN SESHADRI | Officer | 18 Mar 2026 | Sell (-) | 3,610 | 68.24 | 246,346 |
| WAHL BRYAN | Officer | 18 Mar 2026 | Sell (-) | 4,125 | 68.24 | 281,490 |
| WHITFIELD DIANNE C. | Officer | 18 Mar 2026 | Sell (-) | 4,071 | 68.24 | 277,805 |
| AZAMIAN BOBAK R. | Officer | 17 Mar 2026 | Sell (-) | 10,972 | 69.79 | 765,736 |
| FARROW JEFFREY S | Officer | 17 Mar 2026 | Sell (-) | 2,111 | 69.79 | 147,327 |
| LIN ELIZABETH YEU | Officer | 17 Mar 2026 | Sell (-) | 375 | 69.79 | 26,171 |
| MOTTIWALA AZIZ | Officer | 17 Mar 2026 | Sell (-) | 4,286 | 69.79 | 299,120 |
| NEERVANNAN SESHADRI | Officer | 17 Mar 2026 | Sell (-) | 3,125 | 69.79 | 218,094 |
| WAHL BRYAN | Officer | 17 Mar 2026 | Sell (-) | 4,084 | 69.79 | 285,022 |
| WHITFIELD DIANNE C. | Officer | 17 Mar 2026 | Sell (-) | 4,029 | 69.79 | 281,184 |
| LINK WILLIAM J PHD | Director | 16 Mar 2026 | Automatic sell (-) | 12,500 | 68.90 | 861,250 |
| LIN ELIZABETH YEU | Officer | 15 Mar 2026 | Option execute | 2,511 | - | - |
| AZAMIAN BOBAK R. | Officer | 15 Mar 2026 | Option execute | 66,274 | - | - |
| FARROW JEFFREY S | Officer | 15 Mar 2026 | Option execute | 13,042 | - | - |
| MOTTIWALA AZIZ | Officer | 15 Mar 2026 | Option execute | 26,482 | - | - |
| NEERVANNAN SESHADRI | Officer | 15 Mar 2026 | Option execute | 26,287 | - | - |
| WAHL BRYAN | Officer | 15 Mar 2026 | Option execute | 24,236 | - | - |
| WHITFIELD DIANNE C. | Officer | 15 Mar 2026 | Option execute | 23,909 | - | - |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |